Physician profile
Clara Lee
NPI 1639437353
$2,018.11
in general payments reported to CMS, 2019-2025
11 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.12 · 2020: $200 · 2021: $123 · 2022: $232 · 2023: $615 · 2024: $494 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $755.81 | 2021-2025 | Giapreza |
| Astrazeneca Pharmaceuticals LP | $467.87 | 2020-2024 | Andexxa |
| Shionogi INC | $212.39 | 2023-2024 | Fetroja |
| Mallinckrodt Hospital Products INC. | $146.53 | 2025 | Terlivaz |
| Csl Behring | $129.33 | 2024 | Kcentra, Haegarda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.64 | 2023-2025 | Xifaxan |
| Medtronic Vascular, INC. | $81.48 | 2020 | |
| Chiesi USA, INC. | $52.30 | 2024-2025 | Cleviprex |
| Mindray Ds USA, INC. | $20.94 | 2023 | Te X, Te7 Max |
| Abbvie INC. | $17.70 | 2024 | |
| Sanofi Pasteur INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.